インスリン市場規模、シェア、成長分析、製品タイプ別、デリバリー装置別、タイプ別、用途別、流通チャネル別、地域別：2024年～2031年産業別予測

インスリンの世界市場規模は2022年に206億8,000万米ドルと評価され、2023年の209億9,000万米ドルから2031年には236億9,000万米ドルに成長し、予測期間（2024-2031年）のCAGRは1.52％で成長する見通しです。

インスリン市場は、主に糖尿病の世界の有病率の上昇と医薬品開発の進展によって大きな成長を遂げています。糖尿病は世界で最も急速に増加している慢性疾患の一つであり、世界保健機関（WHO）によると2021年には5億3,700万人の成人が罹患すると推定されているため、インスリンの需要は増加の一途をたどっています。しかし、GLP-1受容体作動薬（GLP-1 RA）をはじめとする2型糖尿病に対する新規処方薬のイントロダクションが、この成長軌道を阻害する可能性があります。市場は、Novo Nordisk A/S、Sanofi、Eli Lilly and Companyなどの主要企業が寡占状態を維持しています。さらに、化学製造の進歩が市場拡大に重要な役割を果たしています。注目すべき技術革新には、Novo NordiskのFiasp（インスリンアスパルトとナイアシンアミドを組み合わせて吸収を高める）や、MannkindのAfrezza（針を必要としない初の吸入型インスリン製品）などがあります。さらに、Oramed Pharmaceuticals社は経口インスリンカプセルの第3相臨床試験を進めており、2023年末までに生物製剤承認申請（BLA）を提出する予定です。糖尿病治療がこのような進歩とともに進化する中、市場情勢も治療選択肢や患者ニーズの変化に対応する必要があります。

目次

イントロダクション

• 調査の目的
• 定義
• 市場範囲

調査手法

• 情報調達
• 二次データソースと一次データソース
• 市場規模予測
• 市場の想定と制限

エグゼクティブサマリー

• 市場概要見通し
• 供給需要動向分析
• セグメント別機会分析

市場力学と見通し

• 市場力学
  • 促進要因
  • 機会
  • 抑制要因
  • 課題
• ポーターの分析

主な市場の考察

• 技術分析
• バリューチェーン分析
• 市場のエコシステム
• 特許分析
• 規制情勢
• PESTEL分析
• パイプライン分析
• イノベーションマトリクス
• 主な投資の分析
• 主な成功要因
• 競合の程度
• 顧客と購買基準の分析

インスリン市場：製品タイプ別

• 市場概要
• 即効型インスリン
  • インスリンリスプロ
  • インスリングルリジン
  • テクノスフィアインスリン
• 持続型インスリン
  • インスリンデテミル
  • インスリングラルギン
  • インスリングラルギン-yfgn
  • インスリンデグルデク
• 混合型インスリン
  • NPH/レギュラー
  • プロタミン/リスプロ
  • プロタミン/アスパルト
• バイオシミラー
• その他

インスリン市場：デリバリー装置別

• 市場概要
• ペン
• 輸液ポンプ
• 注射器
• その他

インスリン市場：タイプ別

• 市場概要
• ヒトインスリン
• インスリンアナログ

インスリン市場：用途別

• 市場概要
• 1型糖尿病
• 2型糖尿病

インスリン市場：流通チャネル別

• 市場概要
• 病院
• 小売薬局
• その他

インスリン市場：地域別

• 市場概要
• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ（MEA）
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ地域

競合情勢

• 上位5社の比較
• 主要企業の市場ポジショニング（2023年）
• 主な市場企業が採用した戦略
• 市場における最近の活動
• 主要企業の市場シェア（2023年）

主要企業プロファイル

• Eli Lilly and Company
• Sanofi
• Novo Nordisk A/S
• Biocon
• Boehringer Ingelheim International GmbH
• Tonghua Dongbao Pharmaceutical Co. Ltd.
• Wockhardt
• Julphar
• Novo Nordisk
• Merck & Co., Inc.
• Pfizer Inc.
• AstraZeneca
• Johnson & Johnson
• Biocon Ltd.
• Ypsomed AG
• Gan & Lee Pharmaceuticals
• Bioton S.A.
• Adocia
• Torrent Pharmaceuticals Ltd.
• Ipsen
• Dongbao Enterprise Group Co., Ltd.

Global Insulin Market size was valued at USD 20.68 billion in 2022 and is poised to grow from USD 20.99 billion in 2023 to USD 23.69 billion by 2031, growing at a CAGR of 1.52% during the forecast period (2024-2031).

The insulin market is experiencing significant growth, primarily driven by the rising global prevalence of diabetes and progress in drug development. With diabetes being one of the fastest-growing chronic diseases worldwide-affecting an estimated 537 million adults in 2021 according to the World Health Organization-the demand for insulin continues to rise. However, the introduction of GLP-1 receptor agonists (GLP-1 RAs) and other novel prescription medications for type 2 diabetes may hinder this growth trajectory. The market remains largely oligopolistic, with key players such as Novo Nordisk A/S, Sanofi, and Eli Lilly and Company dominating the landscape. Additionally, advancements in chemical manufacturing are playing a critical role in market expansion. Notable innovations include Fiasp by Novo Nordisk, which combines insulin aspart with niacinamide to enhance absorption, and Afrezza by Mannkind, the first inhaled insulin product that eliminates the need for needles. Furthermore, Oramed Pharmaceuticals is progressing with Phase 3 clinical trials for its oral insulin capsules and is anticipated to file a Biologics License Application (BLA) by the end of 2023. As the diabetes treatment landscape evolves with these advancements, the insulin market must adapt to keep pace with changing therapeutic options and patient needs.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Insulin market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Insulin Market Segmental Analysis

Global Insulin Market is segmented by Product Type, Delivery Device, Type, Application, Distribution Channel, and Region. Based on Product Type, the market is segmented into Rapid-Acting Insulin, Long-Acting Insulin, Combination Insulin, Biosimilar, Others. Based on Delivery Devices, the market is segmented into Pens, Infusion Pumps, Syringes, and Others. Based on Type, the market is segmented into Human Insulin, Insulin Analog. Based on Application, the market is segmented into Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus. Based on Distribution Channel, the market is segmented into Hospitals, Retail Pharmacies, Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Insulin Market

The global insulin market is significantly propelled by the escalating prevalence of diabetes, driven by factors such as sedentary lifestyles, unhealthy dietary choices, and rising obesity rates. As these lifestyle changes lead to higher incidences of both type 1 and type 2 diabetes, there is a growing demand for insulin therapies to effectively manage blood glucose levels. This surge in the patient population, especially in densely populated regions like Asia and Africa, highlights the urgent need for both traditional and innovative insulin solutions. Consequently, healthcare providers and pharmaceutical companies are increasingly focusing on developing advanced insulin formulations to meet the needs of this expanding market.

Restraints in the Global Insulin Market

A significant market restraint for the global insulin market is the high cost associated with insulin therapy, which disproportionately affects individuals in regions with limited healthcare access. The price of advanced insulin analogs, which offer improved efficacy and convenience, can be prohibitively expensive, restricting availability for low-income patients. This financial barrier is especially pronounced in developing countries, where inadequate or nonexistent healthcare reimbursement systems further exacerbate the issue, leading to substantial gaps in essential diabetes management. As a result, many patients may be forced to forgo necessary treatments, ultimately impeding market growth and diminishing health outcomes for those affected by diabetes.

Market Trends of the Global Insulin Market

The global insulin market is experiencing a significant shift towards biosimilar insulin, driven by the expiration of mainstream insulin patents and the push for cost-effective alternatives. Regulatory bodies like the European Medicines Agency (EMA) and the U.S. FDA are facilitating the approval process for biosimilars, effectively enhancing market competition and reducing prices. This trend is expected to not only lower medical costs for patients but also improve access to insulin in high-cost markets, fostering a more inclusive healthcare environment. As healthcare systems prioritize affordability and accessibility, the biosimilar insulin segment is poised to drive substantial growth in the global insulin market.

Table of Contents

Introduction

• Objectives of the Study
• Definitions
• Market Scope

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Market Overview Outlook
• Supply Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Technology Analysis
• Value Chain Analysis
• Ecosystem of the Market
• Patent Analysis
• Regulatory Landscape
• PESTEL Analysis
• Pipeline Analysis
• Innovation Matrix
• Top Investment Analysis
• Key Success Factor
• Degree of Competition
• Customer & Buying Criteria Analysis

Insulin Market by Product Type

• Market Overview
• Rapid-Acting Insulin
  • Insulin Lispro
  • Insulin Lispro
  • Insulin Glulisine
  • Technosphere insulin
• Long-Acting Insulin
  • Insulin Detemir
  • Insulin Glargine
  • Insulin Glargine-yfgn
  • Insulin Degludec
• Combination Insulin
  • NPH/Regular
  • Protamine/Lispro
  • Protamine/Aspart
• Biosimilar
• Others

Insulin Market by Delivery Device

• Market Overview
• Pens
• Infusion Pumps
• Syringes
• Others

Insulin Market by Type

• Market Overview
• Human Insulin
• Insulin Analog

Insulin Market by Application

• Market Overview
• Type 1 Diabetes Mellitus
• Type 2 Diabetes Mellitus

Insulin Market by Distribution Channel

• Market Overview
• Hospitals
• Retail Pharmacies
• Others

Insulin Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Activities in the Market
• Key Companies Market Share (%), 2023

Key Company Profiles

• Eli Lilly and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novo Nordisk A/S
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biocon
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim International GmbH
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Tonghua Dongbao Pharmaceutical Co. Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Wockhardt
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Julphar
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novo Nordisk
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biocon Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ypsomed AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gan & Lee Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bioton S.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Adocia
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Torrent Pharmaceuticals Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ipsen
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dongbao Enterprise Group Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments